Status:

UNKNOWN

Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy

Lead Sponsor:

Royal Brompton & Harefield NHS Foundation Trust

Collaborating Sponsors:

Chelsea and Westminster NHS Foundation Trust

Imperial College Healthcare NHS Trust

Conditions:

Venous Thrombosis

Insulin Resistance

Eligibility:

FEMALE

40-60 years

Phase:

PHASE4

Brief Summary

Ultra-low-dose oral E2/D will have more beneficial effects than trans-dermal HRT on lipids and insulin resistance in postmenopausal women, whilst adverse effects on coagulation will be avoided.

Detailed Description

Following screening for eligibility, women will be studied at baseline and then randomized to one of two groups: Group A administered Femoston Conti - oral oestradiol 17β 0.5 mg/dydrogesterone 2.5 mg...

Eligibility Criteria

Inclusion

  • Healthy and postmenopausal woman who have had a normal ultrasound result
  • Aged 40 - 60 years
  • At least 1 year post last menstrual period (per participant report)
  • BMI 18 - 32
  • Normal mammogram within 2 years of study commencement
  • Continue on any concomitant medications without any change during the study give informed consent

Exclusion

  • Estrogen or androgen therapy during preceding 3 months
  • Use of hormone implants during the preceding 12 months
  • Have received any medications which may interfere with the study (SSRI, antiandrogens,
  • PDE5 inhibitors, DHEA, SERMS)
  • Have a significant psychiatric disorder
  • Have a history of breast or oestrogen dependent cancer
  • Have diabetes, thrombo-embolic disorders (recent MI angina DVT varicose veins or recurrent DVT), cardiovascular disease, liver disease any condition affecting carbohydrate metabolism, uncontrolled hypertension and uncontrolled hyperlipidaemia
  • Untreated endometrial hyperplasia
  • Dubin-Johnson syndrome and Rotor syndrome
  • Undiagnosed vaginal bleeding
  • Women who have had a hysterectomy

Key Trial Info

Start Date :

November 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2015

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT02264743

Start Date

November 1 2013

End Date

November 1 2015

Last Update

October 15 2014

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Chelsea and Westminster NHS Foundation Trust

London, United Kingdom, SW10 9NH

2

Royal Brompton and Harefield NHS Trust

London, United Kingdom, SW3 6NP

3

Imperial College Healthcare NHS Trust

London, United Kingdom, W12 0HS